Background: The increasing use of anti-B cell therapies in managing multiple sclerosis(MS) around the time of conception has raised important considerations for neonates exposed in utero. International recommendations suggest assessing neonatal B cell count in potentially exposed neonates. Practical implementation of cord blood collection at birth requires coordinated care across specialties, including paediatric haematology, neurology and obstetrics. Methods: This workshop, scheduled for 01/30/2025, will address clinical and logistical challenges of neonatal B cell assessments following in utero exposure to anti-B cell therapies. Presentations by MS pregnancy specialists from Toronto,Ontario, will be complemented by collaborative problem-solving among participants, including a paediatric haematologist, MS neurologists, obstetricians, paediatricians, and a quality specialist. A patient with lived experience will contribute to discussions. Results: The workshop will develop a care pathway for cord blood B cell testing, optimizing vaccine scheduling at London Health Sciences Center (LHSC) in London Ontario. Outcomes will include enhanced multidisciplinary collaboration, participant feedback, development of a practical clinical care plan for B cell collection and interpretation and measures of the pathway’s impact on patient satisfaction and clinical decisions. Conclusions: This initiative will improve care for mothers and neonates exposed to anti-B cell therapies, addressing critical gaps in clinical practice through collaboration and a standardized approach.